Universal healthcare now covers 95% of the population in China and, given limited budgets, healthcare payers are struggling to fund both best medical practice and new innovative medicines. To manage their budgets more effectively, substantial changes have been introduced to the market access process […]
The Growing Influence of the Institute of Clinical and Economic Review on Payer Decisions in the US
Health technology assessment (HTA) bodies, like the National Institute for Health and Care Excellence (NICE) in the UK and the Canadian Agency for Drugs and Technologies in Health (CADTH) in Canada, have become increasingly important in countries across the world as arbiters who determine the […]
Research Operations for Secondary Use of Clinical Sites’ EMR
Sponsors’ pharmacovigilance and medical affairs teams frequently gather RWD directly from medical sites for chart reviews, registries, and other observational studies. These sources have also become more attractive sources for RWD to supplement new indication applications, particularly under […]
The Role of Integrated Scientific Advice for the Early Determination of RWE Requirements in HTA and Payer Assessments
Real-world evidence (RWE) is a ubiquitous conversation topic in discussions on the current health technology assessment (HTA) landscape for biotech and biopharma assets. By now it is widely known that RWE is an unavoidable part of drug development and should be given thorough consideration, ideally […]
Pragmatic Randomized Trials: Considerations for Design and Implementation
The 21st Century Cures Act (Cures Act),1 which became law in the United States December 13, 2016, has highlighted the need for robust real-world data to demonstrate effectiveness and safety of healthcare innovations that meet the requirements of regulators and payers alike. Included in the Act is an […]
Current Landscape: Value Assessment Frameworks
This report, “Current Landscape: Value Assessment Frameworks,” analyzed seven existing U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework. It examined the frameworks through the lens of six broad categories: development process, […]
The New Health Economy is Here. Do You Have the Right Knowledge Resources in Place?
The rapid pace of innovation, the rise of consumerism, an aging population, and movement toward price transparency are placing significant pressure on healthcare companies to stay agile and competitive. Understanding the forces affecting drug development, pricing, and prescribing is crucial to […]
The Link Between Drug Prices and Research on the Next Generation of Cures
Drug prices are once again a major focus of public policy in Washington D.C. President Trump has stated that reducing drug prices is one of his highest priorities.1 The administration recently issued new regulations requiring manufactures to list the price of their drugs in television ads. Congress […]
Social Determinants of Health: The Impact on Members, Health Outcomes and the Bottom Line
While healthcare professionals agree that social determinants of health (SDoH) have a major impact on effective patient care, there are few coordinated efforts to identify and address these issues. In this white paper, you'll learn how to: Identify and capture members' social determinants of […]
Leveraging Technology to Reduce Costs in Clinical Trials
Bringing a novel drug or a medical device to market is becoming more and more expensive, time-consuming and complicated. Yet the urgent need for more cures to both treat well-known diseases more effectively as well as fight more rare diseases calls for faster and cheaper drug and device development […]
Evidence Generation and Communication
Health economics and outcomes research (HEOR) and market access agencies provide specialist consultancy support to pharmaceutical and medical device companies throughout the lifecycle (early phase, pre-launch, launch and post-launch) of a technology (pharmaceutical drug or medical device). The […]
Medical Cost Trend: Behind the Numbers 2020
Employer activism is on the rise. Fed up with rising healthcare costs, many American businesses are negotiating contract prices themselves, setting up provider networks and even building a parallel health system to take care of employees at more manageable costs. PwC's Health Research Institute […]
Harnessing the Power of Nontraditional Data in Health Care
Harnessing the power of nontraditional data in health care Applying analytics to clinical and claims data has become essential to improving outcomes and cost management in health care. While this information is very powerful, supplementing it with nontraditional data sources can provide health care […]
Global Oncology Trends 2019
A record number of new oncology drugs has been approved in recent years, bringing new treatment options to patients. However, despite robust levels of pipeline activity, oncology remains a challenging area for research and development. This report examines the productivity and output of the […]
Medical Affairs Reputations: Migraine (US) 2019
Detailed product-level analysis for benchmarking and improving the performance of medical affairs teams in the US How successful are medical affairs teams in meeting physicians' needs? What medical affairs services and support do physicians value most? For which migraine brands are medical […]
A Multistakeholder Discussion on Open Access and Medical Publishing
Over the past two decades, technological developments have led to dramatic changes in how information is distributed and accessed. The internet has altered how readers expect to receive information, moving from print to online reading. In the context of this growing digital infrastructure, there are […]
2018 Specialty Drug Trends
Specialty drugs continue to skyrocket by FDA approvals as well as price. In 2018, high dollar specialty drugs accounted for 44 of the total 59 FDA-approved novel drugs. NPR reported on a recent study which found that specialty drug prices rose 21 percent for oral medications and 13 percent for […]
The Global Use of Medicine in 2019 and Outlook to 2023
The global outlook for medicine use and spending affects the prospects of life sciences companies, insurers and the health of populations around the world. This report includes the latest predictions for the global pharmaceutical market along with geographic, therapy area and channel perspectives. […]
Breaking Through the Hype of Real-World Evidence
Given the increasing availability of real-world health data, the development of credible analyses to help fill the knowledge gap between clinical trials and actual clinical practice is more important than ever. In this white paper, we discuss the expanding use of real-world evidence in healthcare […]
Time to Market: Accelerating Market Access
Getting to market faster clearly has benefits, but there are also potential downsides for drug companies, too. You need to know the options and consider the wider implications. The options for faster market access multiplied in the last three years, with new opportunities available both before and […]
Orphan Drugs in the United States
In the thirty-five years since the passage of the Orphan Drug Act (ODA) in 1983, the structure of development incentives laid out in the legislation has successfully spurred investment and innovation in rare disease therapies. Recent legislative discussion has focused on whether the ODA development […]
Charting Real World Data and Evidence – Activity and Capabilities (2018)
From Patent to Patient: Analyzing Access to Innovative Cancer Drugs
Transitioning Payment Models: Fee-for-Service to Value-Based Care
In a survey of the NEJM Catalyst Insights Council in July 2018, 42% of respondents say they think value-based reimbursement models will be the primary revenue model for U.S. health care. Indeed, this transition is already happening. Respondents report that a quarter of reimbursement at their […]
How Health Plans and Providers Can Collaborate to Improve Care Transitions and Reduce Hospital Readmissions
Download this white paper to learn how sustainable connectivity among physicians, hospitals, caregivers, and patients can help reduce hospital readmissions through the utilization of: Comprehensive data and analytics for patient identification and stratification. Improved care […]
Generating Consensus and Trust for Quality Measurement to Support Value-Based Care
Quality measurement is an integral part of value-based care, yet providers and payers both struggle to define meaningful metrics and leverage quality measurement data to effectively improve care. With more and more revenue shifting into payment models that require all stakeholders to agree on […]
An Evidence-Based Approach to Hiring: Leaders, Physicians, Nurses, and Front Line Staff
The evolution of "evidence-based" medicine changed the healthcare industry. Not that long ago, clinical judgement, anecdotal evidence, and personal experience ruled clinical decision making. Then we discovered that using research to drive decision making, treatment guidelines, and policies vastly […]
Big Data in Pharmaceuticals: Big Opportunities or Big Challenges – or Both?
Every aspect of pharmaceutical research and development involves the generation of huge quantities of data, with the expectation that we can turn this information rapidly into useful knowledge. This can be used to make "data-driven" decisions to better understand and control processes. This derived […]
AHIP Executive Roundtable Discussion Summary
At an event hosted by FierceHealthPayer, sponsored by Medecision, a select group of health insurance executives from across the country gathered in San Diego during the AHIP Institute & Expo to discuss where the healthcare industry is on its journey toward integrating population health models […]
It Takes Two to Tango
Medtech companies are working hard to build better partnerships with IDN customers. However, based on new ZS research, most IDN executives are dissatisfied with the nature of their relationships with medtech suppliers. Medtech leaders apparently recognize the disconnect. In fact, only 25% of the […]
